Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- “Precursor Premium” Proposed at CSIMC Drug Pricing Subcommittee, Yet Further Deliberations Necessary
November 7, 2013
- Online Sales Banned for Three Years after Rx-to-OTC Switch
November 7, 2013
- Chairman Eto of LDP’s Study Group on Drug Industry Policy Calls for “Balance” in Discussions of Special Price Cuts for Long-Listed Drugs
November 7, 2013
- PAFSC’s 2nd Committee on Drugs to Review Afatinib, Brentuximab on November 18
November 7, 2013
- Lawmaker Criticizes Jikei University, Says It Should Return Government Funds
November 6, 2013
- Staff of 1,000 Eyed for PMDA by FY2018: Parliamentary Secretary
November 6, 2013
- 93 MHLW Staff Members Received 2.95 Million Yen from Novartis Pharma from 3rd Quarter of 2008 through 1st Quarter of 2013
November 6, 2013
- Checking of Remaining Drugs Would Save 9.7 Billion Yen Annually: Estimate by Health and Labor Science Research Group
November 1, 2013
- New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium
October 31, 2013
- MHLW Investigating Whether Advertising for Diovan Violates PAL
October 31, 2013
- Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
- Causal Relationship between Tamiflu and Abnormal Behavior Not Identified: PAFSC Subcommittee
October 30, 2013
- Health Ministry Subcommittees Agree to Continue Suspending Recommendation for HPV Vaccines
October 30, 2013
- MHLW Discussing OTC Status for Certain In Vitro Diagnostics
October 30, 2013
- 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
- MHLW Rejects 2 Applicants for Cell-Based Flu Vaccine Subsidy Project
October 29, 2013
- Conclusion of TPP Talks over IP Rights Postponed
October 29, 2013
- Kenporen Calls for Taking 6 APIs Over the Counter
October 29, 2013
- LDP Establishes Study Group on Pharmaceutical Industry Policy; 11 Domestic Drug Makers to Participate
October 28, 2013
- TPP IP Talks Kick Off in Tokyo, Government Task Force to Hold Press Conference on Oct 28
October 25, 2013
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…